deferiprone has been researched along with Left Ventricular Dysfunction in 6 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 5.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| "In patients with severe myocardial siderosis and impaired LV function, combined chelation therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves cardiac function." | 5.13 | Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. ( Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2008) |
| "Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy." | 2.48 | Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012) |
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 1.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arpa, J | 1 |
| Sanz-Gallego, I | 1 |
| Rodríguez-de-Rivera, FJ | 1 |
| Domínguez-Melcón, FJ | 1 |
| Prefasi, D | 1 |
| Oliva-Navarro, J | 1 |
| Moreno-Yangüela, M | 1 |
| Nijjar, PS | 1 |
| Vongooru, H | 1 |
| Tamene, A | 1 |
| Valeti, U | 1 |
| Masri, C | 1 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Tsiapras, D | 1 |
| Fragatou, S | 1 |
| Farmaki, K | 1 |
| Kyrzopoulos, S | 1 |
| Paraskevaidis, I | 1 |
| Voudris, V | 1 |
| Kremastinos, D | 1 |
| Fernandes, JL | 1 |
| Tanner, MA | 1 |
| Galanello, R | 1 |
| Dessi, C | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Pibiri, M | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance[NCT00103753] | Phase 4 | 65 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferiprone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip | 2012 |
2 trials available for deferiprone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial.
Topics: Adolescent; Adult; Deferiprone; Female; Friedreich Ataxia; Humans; Male; Middle Aged; Pilot Projects | 2014 |
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug The | 2008 |
3 other studies available for deferiprone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Topics: Adult; Anemia, Aplastic; Deferiprone; Deferoxamine; Echocardiography; Hemochromatosis; Humans; Iron | 2015 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ec | 2010 |